

PRECEPTORSHIP PROGRAMME

Breast Cancer

**ESMO
PRECEPTORSHIP**

**CAPE TOWN SOUTH AFRICA
9-10 FEBRUARY 2023**

Multidisciplinary management, standards of care, therapeutic targets and future perspectives.

Co-Chairs

Fabrice André, France

Georgia Demetriou, South Africa

ESMO PRECEPTORSHIP PROGRAMME BREAST CANCER

Multidisciplinary management, standards of care, therapeutic targets
and future perspectives

Cape Town, South Africa
9-10 February 2023

CO-CHAIRS

Fabrice André, France
Georgia Demetriou, South Africa

SPEAKERS

Ines Buccimazza, South Africa
Nesrine Chraïet, Tunisia
Judith Didi-Kouko Coulibaly, Ivory Coast
Madani Ly, Mali
Christopher Maske, South Africa
Devan Moodley, South Africa
Bernardo Rapoport, South Africa
Peter Schoub, South Africa
Alicia Sherriff, South Africa
Peter Vuylsteke, Botswana

LEARNING OBJECTIVES

- To learn about screening, diagnosis and staging of breast cancer
- To learn about the biology of breast cancer and its implications in the management of this disease
- To learn about the standard of care management of early, locally advanced and metastatic breast cancer in surgery, radiation therapy and systemic therapy
- To understand the crucial role of multidisciplinary care in the management of breast cancer

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For future details, please refer to esmo.org.

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Thursday, 9 February 2023

09:00-09:05 5'	Opening and welcome	
5'	Welcome from ESMO and objectives of the meeting	Georgia Demetriou, ZA
09:05-10:30 85'	SESSION 1 Rational use of resources	Chair: Fabrice André, FR
25'	Diagnostics	Fabrice André, FR
25'	De-escalation of adjuvant treatment	Georgia Demetriou, ZA
25'	De-escalation of local treatment	Alicia Sherriff, ZA
10'	Discussion	All
10:30-11:00	Coffee break	
11:00-12:25 85'	SESSION 2 Diagnosis	Chair: Georgia Demetriou, ZA
25'	New breast cancer classification: Traditional pathology and molecular subtypes	Christopher Maske, ZA
25'	Prognostic and predictive markers for breast cancer management	Christopher Maske, ZA
25'	Radiology diagnostics work-up	Peter Schoub, ZA
10'	Discussion	All
12:25-14:25 70'	SESSION 3 Local-regional treatments	Chair: Fabrice André, FR
30'	Principles of breast surgery/oncoplastic surgery	Ines Buccimazza, ZA
12:55-13:45	Lunch	
30'	Principles of breast radiation therapy	Alicia Sherriff, ZA
10'	Discussion	All
14:25-17:35 160'	SESSION 4 Early breast cancer	Chair: Georgia Demetriou, ZA
25'	When CT is needed for ER+/HER2- early breast cancer	Devan Moodley, ZA
25'	Endocrine-based therapy for early breast cancer	Nesrine Chraïet, TN
10'	Discussion	All
20'	Clinical case presentations from the audience (2x10')	All
15:45-16:15	Coffee break	
25'	Optimal management of patients with early stage TNBC	Bernardo Rapoport, ZA
25'	Optimal management of patients with early stage HER2+ breast cancer	Georgia Demetriou, ZA
20'	Clinical case presentations from the audience (2x10')	All
10'	Discussion	All
17:35-18:35 60'	SESSION 5 Metastatic breast cancer – Part 1	Chair: Georgia Demetriou, ZA
30'	Luminal breast cancer	Madani Ly, ML
20'	Clinical case presentations from the audience (2x10')	All
10'	Discussion	All
20:00	Dinner	

Friday, 10 February 2023

08:30-09:50 80'	SESSION 6 Metastatic breast cancer – Part 2	Chair: Fabrice André, FR
25'	Metastatic TNBC	Judith Didi-Kouko Coulibaly, CI
25'	Metastatic HER2+ breast cancer	Georgia Demetriou, ZA
10'	Discussion	All
20'	Clinical case presentations from the audience (2x10')	All
09:50-10:15	Coffee break	
10:15-10:40 25'	SESSION 7 Breast cancer and pregnancy	Peter Vuylsteke, BW
10:40-10:45 5'	Closing remarks	Fabrice André, FR

Note: Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion